Current Approach for Treating Anemia in LR-MDS
A medical oncologist outlines approaches to treating anemia in patients with lower-risk myelodysplastic syndromes.
Video content above is prompted by the following:
- What is your current approach for treating anemia in LR-MDS?
- When would you choose ESAs for first-line treatment?
- When would you switch therapies? Would you dose escalate before switching to an EMA (e.g. second-line)?
- What factors lead to a decision to use luspatercept as a first-line treatment?
- When do you dose escalate?
- When do you dose escalate?
- When would you choose ESAs for first-line treatment?
Epcoritamab Delivers Durable Responses in Anthracycline-Ineligible LBCL
December 12th 2024Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.
Read More
Lower Cardiac Risks Found With Second-Generation BTK Inhibitors in B-Cell Hematologic Disorders
December 12th 2024In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, overall cardiac adverse events, and heart failure in patients with B-cell hematologic malignancies.
Read More
